Breaking News Instant updates and real-time market news.

DCTH

Delcath Systems

$2.68

-0.059 (-2.15%)

08:59
10/11/16
10/11
08:59
10/11/16
08:59

Delcath Systems announces new U.S. clinical sites for FOCUS Phase 3 trial

Delcath Systems announces that five new clinical trial sites in the U.S. have been activated in the Company's global FOCUS Phase 3 clinical trial for patients with hepatic dominant ocular melanoma. These accredited centers join several other prestigious centers as active participants in the FOCUS Trial. Currently, Delcath now has a total of 8 cancer centers in the U.S. open for patient enrollment in the FOCUS Trial. The new participating centers are: Ohio State University Comprehensive Cancer Center; MD Anderson Cancer Center; Thomas Jefferson University; Sidney Kimmel Cancer Center; University of Chicago Comprehensive Cancer Center; University of Maryland Greenebaum Cancer Center.

  • 20

    Oct

DCTH Delcath Systems
$2.68

-0.059 (-2.15%)

03/04/16
WBTH
03/04/16
INITIATION
Target $1
WBTH
Buy
Delcath Systems initiated with a Buy at WallachBeth
WallachBeth analyst Bob Ai started Delcath Systems with a Buy rating and $1 price target. The company's Melphalan/HDS is a viable treatment for ocular melanoma, Ai tells investors in a research note.
03/04/16
03/04/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Cheniere Energy Partners LP (CQH), Cheniere Energy Partners (CQP), and Cheniere Energy (LNG) initiated with Overweight at JPMorgan by analyst Jeremy Tonet, who said project catalysts "continuously de-risk the story" and the recent selloff provides a "compelling" entry point. 2. Splunk (SPLK) initiated at Outperform at Macquarie and BMO Capital. Macquarie analyst Sarah Hindlian believes concerns around the company's data-volume-based pricing are overblown, as checks suggest that Splunk's new lower-level entry pricing and cap on unlimited pricing are being well received by customers. BMO Capital analyst Keith Bachman said the company has "a lot of room for growth" with its total addressable market likely to grow 11% on average over the next few years. 3. Workday (WDAY) initiated with an Underperform at Macquarie, with analyst Sarah Hindlian saying the upcoming quarters will begin to show increasing challenges from improved competitor positioning and a more difficult FMS cloud sales. 5. Oracle (ORCL) initiated with an Outperform at Macquarie citing attractive defensive investment for value investors and sentiment that has become overly negative. 5. Delcath Systems (DCTH) initiated with a Buy at WallachBeth by analyst Bob Al, who said the company's Melphalan/HDS is a viable treatment for ocular melanoma. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.